On July 2, Vertex Pharmaceuticals rose 3.25% in regular trading, trading at $516.04/share, with turnover of approximately $90.04 million.

On the news front, the U.S. FDA approved an expanded indication for Vertex's CRISPR-based gene therapy Casgevy, lowering the minimum eligible age from 12 years to 2 years for patients with sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta thalassemia. The company stated this label expansion makes approximately 5,500 additional pediatric patients in the U.S. eligible for the one-time cell therapy.

The approval follows positive Phase 3 data presented in June showing durable benefits in children aged 5 to 11, where all treated patients remained crisis-free and achieved transfusion independence. Regulatory reviews for similar label expansions are currently underway in the UK and Saudi Arabia. This marks another significant label expansion for Vertex in recent months, following FDA approval of broader indications for its cystic fibrosis treatments Alyftrek and Trikafta in April.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)